

**FORM 51-102F3
MATERIAL CHANGE REPORT**

ITEM 1. NAME AND ADDRESS OF COMPANY

Mydecine Innovations Group Inc. (the "Company")
#810 – 789 West Pender Street
Vancouver, BC V6C 1H2

ITEM 2. DATE OF MATERIAL CHANGE

September 18, 2020

ITEM 3. NEWS RELEASE

The news release was disseminated through the facilities of Stockwatch and subsequently filed on SEDAR on September 21, 2020.

ITEM 4. SUMMARY OF MATERIAL CHANGE

The Company announced debt settlement transaction.

ITEM 5. FULL DESCRIPTION OF MATERIAL CHANGE

The Company announced that its board of directors has approved the settlement of a principal amount of \$15,600.00 in debt for services rendered through the issuance of common shares (the "Debt Settlement"). Pursuant to the Debt Settlement, the Company issued 74,286 common shares of the Company (the "Shares") at a deemed price of \$0.21 per Share to a creditor of the Company. All securities issued will be subject to a statutory hold period which will expire on the date that is four months and one day from the date of issuance.

The Company further announces that on September 16, 2020, it cancelled and returned to treasury 529,034 Shares that were originally issued to a former consultant of the Company on May 7, 2020 (the "Share Cancellation"). Following the Debt Settlement and Share Cancellation, the issued and outstanding common shares of the Company is 162,724,412.

ITEM 6. RELIANCE ON SUBSECTION 7.1(2) OR (3) OF NATIONAL INSTRUMENT 51-102

Not Applicable.

ITEM 7. OMITTED INFORMATION

There are no significant facts required to be disclosed herein which have been omitted.

ITEM 8. EXECUTIVE OFFICER

Contact: David Joshua Bartch, CEO
Telephone: (604) 687-2038

ITEM 9. DATE OF REPORT

September 21, 2020